"Have drug costs gone up as a result of this mechanism? Is there any definitive proof? Are there studies that have looked into this question?"This blogger isn't immediately aware of such statistics, but he finds it difficult to imagine that an industry sector as closely monitored and regulated as the pharmaceutical sector, and as closely scrutinised by the competition authorities, could have gone from the early 1990s until now without there being quantities of evidence, both from the two sides of industry and from third parties, to which David might profitably be pointed. If you have a handy reference or weblink to any helpful data, please post it as a comment beneath this blog post -- together with any pertinent comments you may have as to their currency, veracity or objectivity.
A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here